MedTrace Logo

Validation of the LiverFASt Test and the Associated Fibrosis Staging Scores Compared to Liver Tissue Pathology Via Liver Biopsy

NCT03980912 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2021-02-03

No results posted yet for this study

Summary

This study is to assess the diagnostic performance of the LiverFASt Test for assessing fibrosis staging scores compared to the assessment of liver tissue pathology from liver biopsy.

Conditions

  • NAFLD
  • NASH

Interventions

DIAGNOSTIC_TEST

LiverFASt

LiverFASt™ is a blood based diagnostic test utilizing a patented algorithm to determine presence and the progression of liver disease. The test is non-invasive, simple, and less expensive than liver biopsy or liver imaging.

Sponsors & Collaborators

  • OBVIO HEALTH USA, Inc.

    collaborator UNKNOWN

  • Fibronostics USA, Inc

    lead OTHER

Principal Investigators

  • Parth Shah, MD · OBVIO HEALTH USA, Inc.

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-01
Primary Completion
2020-09-01
Completion
2020-11-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03980912 on ClinicalTrials.gov